TRASTUZUMABE DERUXTECANA/PROs T-DXd
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB DERUXTECAN IN THE ONCOCLINIS GROUP
Biomarker: HER+
Critérios de inclusão
Female or male patients with HER+ metastatic malignancy of the breast who will start treatment with T-DXd; Age greater than 18 years.
Critérios de exclusão
Use of other concomitant antineoplastic therapies;
Patients for whom the physician responsible for prescribing T-DXd is from an institution other than the Oncoclínicas Group.
Quer fazer parte do estudo?
Quero fazer parte do estudoPesquisas clínicas
Confira mais informações sobre o programa de pesquisa clínica do Grupo Oncoclínicas.
Saiba mais
